Search

Home > New FDA Approvals > 022 - FDA approves Calquence (acalabrutinib) for adults with MCL; FDA panel backs approval for Indivior's RBP-6000 opioid addiction drug; Novartis submits application to FDA for Kymriah (tisagenlecleucel) for r/r DLBCL; FDA clears 3 antimicrobial suscep


	Podcast:		New FDA Approvals
	Episode:		022 - FDA approves Calquence (acalabrutinib) for adults with MCL; FDA panel backs approval for Indivior's RBP-6000 opioid addiction drug; Novartis submits application to FDA for Kymriah (tisagenlecleucel) for r/r DLBCL; FDA clears 3 antimicrobial suscep
	Category:		Science & Medicine
	Duration:		0
	Publish Date:		2017-11-01 06:00:00
	Description:		November 1, 2017 0:27 FDA approves new treatment for adults with mantle cell lymphoma https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583076.htm https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html 3:20 U.S. FDA panel backs approval for Indivior opioid addiction drug http://www.indivior.com/investor-news/fda-advisory-committees-recommend-approval-indiviors-rbp-6000-treatment-opioid-use-disorder/ 6:30 Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy https://www.reuters.com/article/us-novartis-kymriah/novartis-asks-fda-to-expand-kymriahs-use-against-blood-cancer-idUSKBN1D00QR https://www.novartis.com/news/media-releases/novartis-submits-application-fda-kymriahtm-tisagenlecleucel-adult-patients-rr 10:04 FDA Clears 3 Antimicrobial Susceptibility Tests to Guide Appropriate Use of Baxdelahttp://www.contagionlive.com/news/fda-clears-3-antimicrobial-susceptibility-tests-to-guide-appropriate-use-of-baxdela If we can help with any medical writing, please reach out to us at info@nascentmc.com Our US-based company, Nascent Medical, LLC, has a team of over 100 PhD-/MD-level writers who can write about any medical, scientific or technical topic. We charge a flat rate of $1/word. In some cases we can reduce that rate for larger or ongoing projects or we may need to add to the rate depending on what is needed. Our turn around times can be as short as 1 to 2 days depending on the length of the project, and we don't charge extra for our speediness. Have you updated your blog or posted any press releases lately? That's a small project that some clients like to test us out with to start. We do the following types of writing, including but not limited to: -Video and virtual reality script writing -eLearning scripts -Medical education -Webinar slide creation -Manuscripts -Slidesets -Manuscripts -Press releases -Blog posts -Annual reports -Proposals -White papers -Web content -Posters -Sales training materials
	Total Play:		0